Back Human Papillomavirus (HPV)

Human Papillomavirus (HPV)

Human Papillomavirus Vaccine Is Effective for Women with HIV

HIV positive women respond well to the Gardasil human papillomavirus (HPV) vaccine, offering them protection against cervical cancer, according to a study published in the April 14 electronic edition of Clinical Infectious Diseases. Related recent research found that both Gardasil and Cervarix are effective in people with HIV.

alt

Read more:

FDA Approves HPV DNA Test as Pap Smear Alternative for Cervical Cancer Screening

The U.S. Food and Drug Administration (FDA) last week approved Roche Diagnostics' cobas human papillomavirus (HPV DNA test for initial screening for cervical cancer. The test detects high-risk or cancer-causing HPV types including HPV-16 and HPV-18. Women who test positive for high-risk HPV can then undergo further testing for pre-cancerous or malignant cell changes.

alt

Read more:

Black Women More Likely to Carry Human Papillomavirus Strains Not Covered by Vaccines

African-American women with precancerous cervical abnormalities are about half as likely to have cancer-causing human papillomavirus (HPV) types 16 and 18, and more likely to have other types for which the Gardasil and Cervarix vaccines do not provide protection, according to a study presented at the American Association for Cancer Research International Conference on Frontiers in Cancer Prevention Research taking pace this week in Maryland.

alt

Read more:

CROI 2014: Natural History of HIV-Related Anal Dysplasia [VIDEO]

The progression of anal dysplasia is highly variable in people with HIV, progressing in some and remaining stable or regressing in others, according to a retrospective analysis of nearly 3000 participants presented at the 21st Conference on Retroviruses and Opportunistic Infections (CROI 2014) last week in Boston. Progression to invasive anal cancer, however, was uncommon.

alt

Read more:

EACS 2013: Ensuring Good Quality HIV Care in Europe: Where Can We Improve?

Only 20% of people with HIV in Europe have fully suppressed viral load, compared to an estimated 24% in sub-Saharan Africa, despite much higher rates of HIV diagnosis in the European region, Professor Jens Lundgren of the University of Copenhagen told the 14th European AIDS Conference in Brussels on Saturday.

alt

Read more: